Apollo endosurgery products to take center stage at digestive disease week

Austin, tx / accesswire / may 18, 2022 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that apollo products and procedures that utilize apollo products will be featured in more than 40 academic posters and videos and over 60 podium presentations and lectures at the upcoming digestive disease week 2022 to be held in san diego, may 21-24. highlights include: full presentation of the merit study of the endoscopic sleeve gastroplasty (esg) procedure's impact on obesity (presentation 995) 5-year follow-up data for endoscopic sleeve gastroplasty (presentation 687) endoscopic sleeve gastroplasty in class iii obesity (presentation 996) a systemic review and meta-analysis comparison of esg and laparoscopic sleeve gastrectomy (presentation 51) revisional endoscopic sleeve gastroplasty and glp-1 agonist medications (presentation 295) a multicenter study of the efficacy, feasibility and safety of the x-tack® endoscopic helix tacking system (presentation 388) closure of colonic emr defects using the x-tack® endoscopic helix tacking system (su1434) "apollo endosurgery's products and our customers have played a critical role in driving the field of therapeutic endoscopy forward, to the betterment of patient care," commented chas mckhann, president and ceo of apollo.
APEN Ratings Summary
APEN Quant Ranking